Sponsored By

The Deerfield, IL-based company is calling the spinoff Vantive.

Omar Ford

July 25, 2023

1 Min Read
IMG_2023-07-25-100828.jpg
Image Credit: Olivier Le Moal via iStock / Getty Images

Earlier this year, Baxter joined the spinoff revolution that dominated much of 2022 by announcing it would spin out its renal care and acute therapies businesses.

Now, nearly eight months after the announcement the Deerfield, IL-based firm has found a name for the new company - Vantive.

In a release, Baxter said that Vantive is expected to launch as an independent, publicly-traded company by July 2024 or earlier.

“Announcing the Vantive name is a critical milestone in our journey to becoming an independent company focused solely on therapies for kidney disease and other vital organ support,” said Chris Toth, executive vice president and group president, Kidney Care at Baxter, who is to serve as CEO. “The Vantive name reflects our dedicated employees’ steadfast commitment to patients and our passion for helping them lead full and meaningful lives in partnership with our customers. We are eager to continue collaborating with the kidney and critical care communities as we work to transform care globally.”

Baxter noted Vantive’s logo and full visual identity will be unveiled at a later date. Until the completion of the proposed separation in 2024, the Kidney Care business will continue to operate as Baxter.

When the spinout is complete, Vantive will have some serious competition in the Renal Care market.

Medtronic and DaVita have announced the creation of a new medtech company, which develops kidney care products and solutions, including future home-based products, to make different dialysis treatments more accessible to patients.

Fresenius Health Partners leveled up its offerings when it said it would enter a three-way merger with InterWell Health, a physician organization driving innovation in the kidney care, space and Cricket Health, a provider of value-based kidney care with a patient engagement and data platform.

About the Author(s)

Omar Ford

Omar Ford is MD+DI's Editor-in-Chief. You can reach him at [email protected].

 

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like